Shots:

• The P-II BLAZE-1 study assesses bamlanivimab (700- 2800 & 7000 mg) vs PBO in the outpatient setting in patients with mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than 3 days prior to drug infusion
• Results: The study showed that bamlanivimab may be effective in treating COVID-19 by reducing viral load- symptoms and the risk of hospitalization in patients recently diagnosed with mild to moderate COVID-19
• LY-CoV555 is a neutralizing IgG1 mAb directed against the spike protein of SARS-CoV-2 & designed to block viral attachment and entry into human cells- thus neutralizing the virus- potentially preventing & treating COVID-19

  Ref: PRNewswire | Image: Business Insider